Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
GC-MS and GC-MS/MS measurement of malondialdehyde (MDA) in clinical studies: Pre-analytical and clinical considerations.
J Mass Spectrom Adv Clin Lab
November 2023
Hannover Medical School, Institute of Toxicology, Core Unit Proteomics, 30623 Hannover, Germany.
Malondialdehyde (MDA; 1,3-propanedial, OHC-CH-CHO) is one of the most frequently measured biomarkers of oxidative stress in plasma and serum. L-Arginine (Arg) is the substrate of nitric oxide synthases (NOS), which convert L-arginine to nitric oxide (NO) and L-citrulline. The Arg/NO pathway comprises several members, including the endogenous NOS-activity inhibitor asymmetric dimethylarginine (ADMA) and its major metabolite dimethyl amine (DMA), and nitrite and nitrate, the major NO metabolites.
View Article and Find Full Text PDFN-Acetyl-L-cysteine in human rheumatoid arthritis and its effects on nitric oxide (NO) and malondialdehyde (MDA): analytical and clinical considerations.
Amino Acids
September 2022
Clinic for Rheumatology und Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
N-Acetyl-L-cysteine (NAC) is an endogenous cysteine metabolite. The drug is widely used in chronic obstructive pulmonary disease (COPD) and as antidote in acetaminophen (paracetamol) intoxication. Currently, the utility of NAC is investigated in rheumatoid arthritis (RA), which is generally considered associated with inflammation and oxidative stress.
View Article and Find Full Text PDFHydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review.
Front Pharmacol
December 2020
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
Article Synopsis
- Hydroxychloroquine has been considered as a potential drug for preventing COVID-19 due to its ability to inhibit SARS-CoV-2 in lab settings, but evidence from animal studies and clinical trials shows mixed results on its effectiveness.
- Issues such as inadequate drug concentrations and the effect of specific proteins in the respiratory system may contribute to its limited success in real-world applications.
- Ongoing clinical trials and safety concerns about higher doses highlight the need to explore alternative prevention strategies for high-risk populations.
Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services.
Psychooncology
May 2019
Biomedical Research Institute (IIB Sant Pau), Iberoamerican Cochrane Centre, Barcelona, Spain.
Article Synopsis
- - Women's preferences are key in shaping breast cancer screening guidelines, especially given the mixed views on its benefits versus harms.
- - A systematic review of 22 studies revealed that women are willing to endure the mental and physical challenges of screening for the chance of an earlier diagnosis, despite risks of overdiagnosis and false positives.
- - There is a significant emphasis on the need for quicker testing and better communication since the delay in getting results is a major source of anxiety for women, highlighting that while they value early diagnosis, understanding the risks like overdiagnosis remains a concern.
Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
Invest New Drugs
April 2017
Department of Medical Oncology, Cochin - Port Royal Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité 123, Boulevard de Port-Royal, 75014, Paris, France.
Background Older non-small cell lung cancer (NSCLC) patients under erlotinib are reported to experience more acute toxicity. We hypothesized that modifications in erlotinib pharmacokinetics might explain this observation. Methods A monocentric prospective clinico-pharmacological study included stage IIIb/IV NSCLC consecutive pts.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!